Skip to main content

Rethymic FDA Approval History

Last updated by Judith Stewart, BPharm on Nov 4, 2021.

FDA Approved: Yes (First approved October 8, 2021)
Brand name: Rethymic
Generic name: allogeneic processed thymus tissue-agdc
Dosage form: for Surgical Implantation
Company: Enzyvant Therapeutics, Inc.
Treatment for: Congenital Athymia

Rethymic (allogeneic processed thymus tissue-agdc) is a one-time regenerative tissue-based therapy indicated for immune reconstitution in pediatric patients with congenital athymia.

Development timeline for Rethymic

Oct  8, 2021Approval FDA Approves Rethymic (allogeneic processed thymus tissue-agdc) One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.